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Abstract Activation-induced cytidine deaminase (AID)
is critically involved in class switch recombination and
somatic hypermutation of Ig loci resulting in diversification
of antibodies repertoire and production of high-affinity
antibodies and as such represents a physiological tool to
introduce DNA alterations. These processes take place
within germinal centers of secondary lymphoid organs.
Under physiological conditions, AID is expressed pre-
dominantly in activated B lymphocytes. Because of the
mutagenic and recombinogenic potential of AID, its
expression and activity is tightly regulated on different
levels to minimize the risk of unwanted DNA damage.
However, chronic inflammation and, probably, combina-
tion of other not-yet-identified factors are able to create a
microenvironment sufficient for triggering an aberrant AID
expression in B cells and, importantly, in non-B-cell
background. Under these circumstances, AID may tar-
get also non-Ig genes, including cancer-related genes as
oncogenes, tumor suppressor genes, and genomic stability
genes, and modulate both genetic and epigenetic informa-
tion. Despite ongoing progress, the complete understanding
of fundamental aspects is still lacking as (1) what are the
crucial factors triggering an aberrant AID expression/
activity including the impact of Th2-driven inflammation
and (2) to what extent may aberrant AID in human non-B
cells lead to abnormal cell state associated with an
increased rate of genomic alterations as point mutations,
small insertions or deletions, and/or recurrent chromosomal
translocations during solid tumor development and
progression.
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AID under physiological conditions
Adaptive immunity provides defense mechanisms ensuring
extreme specificity for foreign antigens with virtually
unlimited diversity. B lymphocytes have developed two
additional independent steps to further diversify their
receptors after antigen collision: somatic hypermutation
(SHM) and class switch recombination (CSR). These
reactions take place in secondary lymphoid tissues (lymph
nodes, tonsils, and spleen) and represent physiological
processes that modify variable (V) and constant (C) regions
of immunoglobulin (Ig) genes in activated B cells [1]. The
discovery of AID [2, 3] (in 1999—mouse ortholog; in
2000—human ortholog) transformed our understanding of
basic mechanisms for antibody diversity and the field of
immunology as a whole; both SHM and CSR were found to
be critically dependent on AID activity.
AID is a member of the APOBEC family of cytidine
deaminases, which acts via introduction of single-strand
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breaks into target DNA through deamination of cytosines
into uracils. AID is currently considered as the only B-cell-
specific factor required to trigger both SHM and CSR,
when DNA breaks are specifically introduced in the vari-
able or switch regions of Ig genes, respectively [4, 5].
Through further processing by DNA-repair enzymes upon
recognition of uracil in DNA, this initial single biochemi-
cal activity triggers different genetic modifications [6, 7].
As consequence, the production of Igs of various isotypes
with high affinity for antigen is achieved. This may espe-
cially account for IgE type immunoglobulins exhibiting
outstanding affinities for their specific epitopes or aller-
gens. In the germinal center (GC), the AID expression is
initiated in early centroblasts, is maximal in full-blown
centroblasts, significantly decreases in centrocytes, and is
downregulated again in plasma cells. Additionally, the
AID-positive cells could be also detected outside the GC; a
major fraction of these types of AID-positive cells reside
within the subset of interfollicular large B lymphocytes
[8, 9].
AID deficiency (as well as defects in the CD40L/CD40
pathway) is among essential causative factors of hyper-IgM
(HIGM) syndromes. HIGM are primary immunodeficien-
cies characterized by the absence of all the isotypes except
for elevated IgM [10]. The phenotype observed in HIGM
patients and paradoxical observation that AID-deficient
subjects often suffer from autoimmune conditions demon-
strate the absolute requirement for AID in several crucial
steps of B-cell terminal differentiation and suggest an
important role of AID for the establishment of both central
and peripheral B-cell tolerance. Thus, Meyers et al. [11]
identified a novel, previously unsuspected role for AID in
the removal of developing autoreactive B cells in humans.
Accumulating evidence suggests another essential role
of AID—in two forms of heritable information, namely
genetic and epigenetic. The underlying mechanisms behind
these two modes of inheritance have so far remained dis-
tinct. Given that cytosine deaminases, and particularly
AID, have been implicated both in genetic variation of
somatic cells and in epigenetic remodeling of germ and
pluripotent cells, an audacious hypothesis was proposed by
Chahwan et al. [12] that the AID/APOBEC family provide
crosstalk between genetic and epigenetic information
through cytosine deamination and, moreover, could be
important drivers of evolutionary adaptability.
Multiple levels of AID regulation
Clearly, such a potent mutagenic and recombinogenic
enzyme needs to be tightly regulated on different levels to
minimize the risk of unwanted DNA damage (Fig. 1).
Indeed, a number of mechanisms restricting AID
expression/activity to a distinct cell type, time, and loci
were identified. On the transcriptional level, AID is
induced in vitro in B cells by Th2 cytokines as IL4 and
ligation of CD40; in mice, other inducers have been
identified, including LPS [3, 13, 14]. E-protein, NFjB,
PAX5, STAT6, and IRF8 transcription factors participate
in inducible expression of AID; potential negative regula-
tors, such as IRF4, BLIMP1, ID3, and ID2, may control the
stage-specific expression (reviewed by [15]); however, our
understanding of the transcriptional regulation of AID gene
is not yet complete. In one of the recent publications,
HoxC4 was implemented into the AID promoter regulation
via binding to a highly conserved HoxC4-Oct site; this site
functions in synergy with a conserved binding site for the
transcription factors Sp1, Sp3, and NF-jB [16]. Further-
more, AID is known to be regulated on the level of mRNA
stability by microRNAs [17–19]. An additional controlling
mechanism, which is not yet fully elucidated, is the splic-
ing of AID mRNA. The naturally occurring splice variant
lacking exon 4, AID-Dex4 (AY536517), encodes a C-ter-
minally truncated product, which, in contrast to the full-
length transcript, is characterized by the complete lack of
Fig. 1 AID-associated gene network. Gene network displaying AID
as key gene was created using the Ingenuity Pathway Analysis
Software (IPA; http://www.ingenuity.com). Different gene modules
are spatially separated for visualization: stimuli controlling AID
expression and activity (green color code); transcriptional regulators
(red color code); an additional level of AID regulation is displayed by
a group of miRNAs (brown color code); direct and indirect AID-
interacting molecules associated with functional activity of AID (blue
color code); molecules modulated by AID activity including various
Ig isotypes as consequence of CSR events and examples of affected
pluripotency genes as a result of AID-mediated reprogramming and
DNA demethylation as well as TP53 being a prominent target of AID
as genome-wide mutator (cyan color code)
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CSR activity, while showing hyper-SHM activity [20]. It is
essential to note that based on our recent data, both AID
full-length and AID-Dex4 mRNAs can be detected in
chronically inflamed tissues such as nasal polyps and in
some normal non-lymphatic tissues as well [21]. Post-
translational modification as phosphorylation of threonine
27, threonine 140, and/or serine 38 also regulates AID
activity [22–24]. One of the crucial post-translational
mechanisms controlling AID functionality including the
balance between antibody diversification and off-target
mutations and translocations is based on the nucleo-cyto-
plasmic shuttling: the subcellular localization of AID
determines how much AID is in contact with genome.
Currently, the following mechanisms influencing human
AID subcellular distribution have been characterized:
nuclear export [25–27], active nuclear import and cyto-
plasmic retention [28], and rapid degradation in the nucleus
[29]. Finally, even when AID expression/activity is being
controlled by multiple mechanisms, one important cellular
mechanism, which determines the target specificity of AID,
still must function properly. This is yet one of the most
interesting questions in AID biology: how does the pref-
erential targeting to Ig loci work and why the specificity of
AID is not absolute? It seems that AID recruitment to the
particular genes requires a combination of high transcrip-
tional activity of a gene, the presence of high levels of AID
targeting hotspots, the presence and activity of protein
kinase A, which phosphorylates AID at DNA site, and a
complex of cis elements (reviewed in [30, 31]). Future
comprehensive genome-wide screening of mutated genes
and gene fusions will provide a more defined picture of the
mechanisms regulating AID targeting.
AID in inflammatory processes
It is generally accepted that expression of AID and class
switch process occur in lymphoid tissue. Important novel
aspect linking B-cell biology and inflammation is based on
the discovery of GC-like structures outside of secondary
lymphoid organs. Accumulating evidences demonstrate the
existence of AID-positive ectopic follicular structures at
sites of inflammation within different tissues, suggesting
class switch recombination and somatic hypermutation
events to take place locally. One of the pioneer work [32]
has demonstrated that IgE-committed B cells do not nec-
essarily need to migrate through the circulation to the nasal
mucosa; detection of AID mRNA, multiple germline gene
transcripts, and e circle transcripts in the nasal mucosa of
allergic subjects indicated that CSR occurs locally in
allergic rhinitis. Later, local expression of AID and CRS
to IgE was shown in the bronchial mucosa of atopic and
non-atopic patients with asthma [33]. Additionally, the
esophageal mucosa was proposed to be a site for initiation
and development of humoral responses given the occur-
rence of AID expression, local immunoglobulin class
switching to IgE, and IgE production in the esophageal
mucosa of patients with eosinophilic esophagitis [34].
Indeed, the esophageal mucosa possesses a strong immu-
nological capacity based on a diversity of resident immune
cell types, in particular, B lymphocytes, T cells, mast cells,
and dense eosinophilic infiltration as well as the presence
of Th2 cytokines IL4 and IL13. The authors suggested that
sensitisation and activation of mast cells involving local
IgE may critically contribute to the pathogenesis of
eosinophilic esophagitis. Furthermore, recent findings
indicate that the presence of AID-positive ectopic lym-
phoid structures can be detected in chronically inflamed
tissues in several autoimmune disorders [35]; in synovium
of rheumatoid arthritis, the AID-positive follicular struc-
tures are directly implemented in promoting the production
of pathogenic autoantibodies [36]. The data suggest that
tissues under constant antigenic challenge (e.g., the intes-
tinal, nasal and bronchial mucosa) support B-cell activa-
tion, AID expression, isotype switching, and Ig production.
It is yet unclear what the crucial endogenous checkpoints
are being necessary for mounting a limited, positively
effective inflammatory response with participation of B
lymphocytes and what the borderline is converting the
physiological ectopic follicles to the pathophysiological
autoantibody-producing structures.
Multigene signature approach to delineate the role
of AID-driven events under Th2 supervision
The establishment and validation of gene-, pathway-, or
disease-relevant signatures provides tools for understand-
ing the functional relevance of gene alterations in human
diseases not only for basic research but also for therapeutic
target proposal, diagnostic tools, and therapy response
monitoring [37–40]. The implemented methodology to
study gene expression profiles of modules with particular
biological function(s) in the etiology of disease may vary:
(1) in silico data-driven approaches using microarray data
analysis offer the advantage of a transcriptome-wide
screening procedure but often lack the sensitivity for genes
expressed at low levels; (2) a knowledge-driven approach
offers the detailed characterization of the input of one
particular pathway while keeping the amount of genes
limited at the beginning of the study. In this case, the
composition of a core set of genes can be assembled based
on the data mining (scientific literature, creation of gene
interactive networks) with subsequent application of the
designed multigene signature for real-time PCR-based
gene profiling. Thereby, the important advantages are the
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high sensitivity and reproducibility allowing quantitative
profiling even of low-copy genes that are below the
detection limits of microarray platforms.
We have used recently the second approach to create the
multigene signature using AID (NM_020661) as a node
gene [21]. The self-designed 25-gene ‘‘AID signature’’
included the full-length AID-FL and the alternative AID
splice variant AID-Dex4; activators and suppressors in AID
regulation; immune cell markers; Th2 cytokines; low- and
high-affinity IgE receptors; and IgM, IgG, IgE mature
transcripts (Fig. 2). This signature was evaluated in a dis-
ease model of benign, chronically inflamed tissue, namely
in nasal polyposis. In this study, we have shown, to our
knowledge, for the first time that AID is expressed within
the nasal polyp tissue. Comparison of gene expression
patterns for chronic rhinosinusitis with and without nasal
polyps confirmed an AID-specific gene signature for the
disease state with nasal polyps. The data suggested that the
local environment created within nasal polyp tissue may
trigger formation of ectopic follicular structures with AID
expression/activity and consequently initiate CSR. This
was in turn proven by the detection of strongly elevated
IgG and, particularly, IgE mature transcripts, fully sup-
ported by immunostaining. Notably, AID mRNA was
found to have a strong positive correlation with Th2
players IL13 and IL5. Furthermore, arrangement of data-
sets for each specimen across all genes was able to provide
the gene expression pattern characteristic for each indi-
vidual sample and therefore being patient orientated. Thus,
using a multigene signature covering one particular dis-
ease-associated module with AID as the key gene, we
further explored associations between AID and other
molecules involved in the etiology of human inflammation-
driven disease such as nasal polyposis: in addition to the
previously highlighted biomarkers/targets such as IgE and
IL5, novel players were suggested including among others
IL13 and CD23 [21].
Multifaceted AID: functional link to tumorigenesis
Last years findings clearly indicate that, in addition to
diversifying the immune repertoire, AID can also target
non-Ig genes. Thus, an aberrant hypermutation activity
targeted multiple loci, including the proto-oncogenes
PIM1, MYC, RhoH/TTF (ARHH), and PAX5, in more than
50 % of diffuse large-cell lymphomas (DLCLs), which are
tumors derived from germinal centers [41]; human BCL6
gene was shown to be also hypermutated in peripheral
blood memory B cells and tonsils [42]. Intriguingly, even
the T-cell receptor in AID-transgenic mice [43] and a GFP
plasmid reporter gene in AID-transgenic fibroblasts [5]
were shown to hypermutate. Wang et al. demonstrated that
hypermutation requires no Ig gene sequences; instead, AID
(and possibly other trans-acting hypermutation factors)
may function as general, genome-wide mutator [44]. Thus,
by mutating multiple genes, and possibly by favouring
chromosomal translocations, AID-driven aberrant, non-
physiological hypermutation likely represents one of the
major contributors to lymphomagenesis. In support, AID
acts as mutator in the Philadelphia chromosome plus (Ph?)
BCR-ABL1-transformed acute lymphoblastic leukemia
(ALL) cells [45].
If to look deeply and make approximation to other types
of tumors, the link between functionality of AID and
malignancies becomes more transparent and logical: cancer
cells acquire tumor-specific DNA alterations, including
multiple somatic mutations of tumor-promoting genes and/
or recurrent chromosomal translocations and their corre-
sponding gene fusions at the precise timing during cellular
development. A total of 358 gene fusions involving 337
different genes have been identified (reviewed in [46]). An
increasing number of gene fusions are being recognized as
important diagnostic and prognostic parameters in distinct
malignant disorders. Then, abnormal AID expression and
Fig. 2 Th2-type AID-associated multigene signature. The composi-
tion of the signature created around AID as a node gene allows to
assess (1) AID expression and AID activity as proven by the class
switch recombination-based formation of IgG and IgE mature
transcripts; (2) the presence of tissue infiltrating immune cells such
as B cells, T cells, monocytes, and follicular dendritic cells being
indicative for various stages of lymphoid organization; (3) the
expression pattern of low- and high-affinity IgE receptors mediating
numerous IgE-related immune responses; and Th2 polarization [21]
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functionality in non-B cells could have a strong contribu-
tion to human malignancy in general, including solid
tumors (Fig. 3); probably, not only the level of overex-
pression but also constitutive versus transient manner is
important. Indeed, accumulating evidences suggest that an
aberrant AID activity in epithelial tissues may provide the
critical link between inflammation, somatic mutations, and
cancer development [47]. Given the analogy to the mech-
anisms of AID activation in B cells, Th2 direction might
play an essential role. Thus, the potential contribution of
AID to the development of gastric cancers was proposed
[48]. Constitutive AID expression was detected in 6 out of
6 malignant epithelial cells of breast cancer origin and the
cell line derived from uterine cervix, suggesting a potential
for inducible aberrant mutational activity [49, 50]. AID
expression leading to increased mutation rate of TP53 was
recently shown in human lung cancer cell lines [51]. The
proinflammatory cytokine-induced production of AID was
proposed to link bile duct inflammation to cholangiocar-
cinogenesis [52]. AID expression was shown to be
triggered by TNF-a or IL-1b in human hepatocytes [53].
Strong evidence indicates that AID might contribute to
the development of colitis-associated and inflammatory
bowel disease (IBD)-associated colorectal cancers by
linking colonic inflammation to an enhanced genetic
susceptibility to oncogenic mutagenesis [54–56]. Impor-
tantly, aberrant AID expression in human colonic epithe-
lial cells was induced by TNF-a via NFjB-dependent
pathway and by Th2-driven cytokines IL4 and IL13 in a
STAT6-dependent manner. Both cytokines are critical
mediators of mucosal inflammation; accordingly, IL13
secreted by natural killer T cells is an important patho-
logic factor for ulcerative colitis [57]. Furthermore, it has
been shown that several oncogenic viruses can induce
AID expression. Hepatitis C virus (HCV)—one of the
leading causes of hepatocellular carcinoma—strongly
triggers AID expression in hepatocytes in collaboration
with proinflammatory cytokines [53], and ectopic AID
expression is observed in human liver specimens with
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Fig. 3 AID from immunity to cancer. a Somatic hypermutation
(SHM) and class switch recombination (CSR) of B-cell immuno-
globulin (Ig) genes are AID driven. Recently, a new role for AID in
active DNA demethylation and reprogramming of mammalian
somatic cells toward pluripotency has been identified [65]. Further-
more, requirement for AID in several crucial steps of B-cell terminal
differentiation and for the establishment of both central and peripheral
B-cell tolerance was proposed [11]. Accumulating evidence suggests
that the AID/APOBEC family members could be important drivers of
evolutionary adaptability [12]. b Under pathophysiological circum-
stances, AID may target non-Ig genes, including cancer-related genes
as oncogenes, tumor suppressor genes, genomic stability genes, and
pluripotency genes [42, 45, 47, 51, 66]. Picture insert; AID-positive
GCs within tonsil tissue. To detect AID, mouse IgG1-kappa
antibodies, clone ZA001 (Invitrogen) and DAKO EnVision?,
Peroxidase system (DAKO, Glostrup, Denmark) was used as
previously described [21]
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[58]. Another intriguing evidence linking oncogenic
infection with ectopic AID expression is attributed to
Epstein–Barr virus (EBV); LMP2A, EBV latent mem-
brane protein 2A, is able to strengthen B-cell receptor
(BCR)-mediated signaling pathways leading to the AID
activation [59]. However, thus far such mechanism was
demonstrated only for B cells, emphasizing a potential
role for the development of the EBV-positive, GC-asso-
ciated lymphomas [60]. Next potential link of AID to
tumorigenesis is based on the fact that the Aid and Apo-
bec1 genes are located in a cluster of pluripotency genes
including Nanog and Stella and are co-expressed with
these genes in oocytes, embryonic germ cells, and
embryonic stem cells. These data suggest that AID and
perhaps some of other APOBEC family members may
have roles in epigenetic reprogramming and cell plastic-
ity, contributing to tumor etiology [61]. An important
functional link was identified between estrogen and AID:
estrogen directly activates expression of AID [62]
revealing yet another connection between AID regulation
and cancer, particularly the gender aspect for some can-
cers. Therefore, in tissues where estrogen levels are
continuously high, AID-driven aberrations may accumu-
late with time, which in turn might contribute to the
development and/or progression of estrogen-dependent
tumor types. In analogy, female gender bias in allergy
associated with endogenous and exogenous estrogens [63]
may be caused by the AID/estrogen axis.
Although the major focus of the data summary in this
sub-chapter of the article was given to the AID-positive
tumor cells, tumor-associated AID-positive B cell should
not be underestimated. Hypothetically, identification of
AID-positive B-cell infiltrates indicates local maturation
and priming for class switching. Moreover, infiltrating
B cells might modulate the malignant potential of
tumor cells via the production of certain chemokines or
cytokines. Therefore, the biological responses initiated
within AID-positive ectopic follicular structures in the
tumor or tumor-stroma microenvironment may influence
the disease pathogenesis, progression and/or disease
resolution.
Increasing knowledge about AID, understanding the
AID-associated responses, both in B cells and tumor cells,
might allow stratifying the prognosis of various cancer
types and considering whether targeting of AID is benefi-
cial for AID-positive tumors as suggested recently for
plasmocytoma [64] and colitis-associated colon carcino-
genesis [55].
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